Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06200233

Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor

A Phase II, Open-label, Single-arm, Multi-center Clinical Trial of Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor

Sponsor: Samsung Medical Center

Conditions Thymic Epithelial Tumor

Interventions Rivoceranib

Updated 5 times since 2024 Last updated: Apr 8, 2024 Started: May 1, 2024 Primary completion: Mar 1, 2026 Completion: Dec 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Thymic Epithelial Tumor, this trial is actively recruiting participants. The trial is conducted by Samsung Medical Center and has accumulated 5 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Not Yet Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
Feb 2024 — May 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea